 |
12 Diseases |  |
138 Trials |
|
138 Trials |  |
3994 News |  |
| «12...28293031323334353637383940» |
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity (clinicaltrials.gov) - Mar 31, 2020
P1, N=68, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (clinicaltrials.gov) - Mar 26, 2020
P3, N=160, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: STEP 4: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (clinicaltrials.gov) - Mar 25, 2020
P3, N=902, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial initiation date: SWIFT: Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV (clinicaltrials.gov) - Mar 25, 2020
P=N/A, N=80, Not yet recruiting, Sponsor: University College Dublin
Active, not recruiting --> Completed Initiation date: Feb 2020 --> Jul 2020
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, Real-world evidence, Real-world: SURE NL: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS) (clinicaltrials.gov) - Mar 25, 2020
P=N/A, N=217, Active, not recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Feb 2020 --> Jul 2020 Enrolling by invitation --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly, semaglutide SC once-daily (NN9536) / Novo Nordisk
Efficacy and Safety of Semaglutide 0.5 mg vs Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 7 (poster area 3) - Mar 22, 2020 - Abstract #DDG2020DDG_337;
Premature discontinuation due to GI AEs occurred in 5% of subjects in each arm. In summary, semaglutide 0.5 mg showed similar improvements in glycemic control and greater weight loss vs dulaglutide 1.5 mg at week 40, while showing similar tolerability in subjects with T2D.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
Efficacy and Safety of Semaglutide by Baseline BMI in SUSTAIN 1–5 and 7 (poster area 3) - Mar 22, 2020 - Abstract #DDG2020DDG_336;
In conclusion, the efficacy of semaglutide in lowering HbA1c does not appear to be influenced by BL BMI. Semaglutide had an acceptable safety profile in all BMI subgroups.
- Efficacy of Semaglutide by Background Sodium-glucose Co-transporter-2 Inhibitor: a Post Hoc Analysis of SUSTAIN 9 (poster area 3) - Mar 22, 2020 - Abstract #DDG2020DDG_335;
SUSTAIN 9 investigated semaglutide 1.0 mg vs placebo as add-on to a stable dose of sodium – glucose co transporter-2 inhibitor (SGLT-2i) therapy, with or without metformin or a sulfonylurea...In this post hoc analysis, SUSTAIN 9 data were analyzed by background SGLT-2i (empagliflozin, canagliflozin, dapagliflozin or other [ipragliflozin, luseogliflozin and tofogliflozin; drugs available only in Japan])...No diabetic ketoacidosis or lower limb amputation events occurred. In conclusion, in subjects with T2D already receiving an SGLT-2i, semaglutide generally resulted in superior HbA1c and body weight reductions vs placebo, regardless of background SGLT-2i therapy.
- || metformin / Generic mfg., Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Journal: Once-Weekly Semaglutide Reduces HbA and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10. (Pubmed Central) - Mar 21, 2020
P3
In conclusion, in subjects with T2D already receiving an SGLT-2i, semaglutide generally resulted in superior HbA1c and body weight reductions vs placebo, regardless of background SGLT-2i therapy. Semaglutide 0.5 mg and 1.0 mg significantly improve glycaemic control (HbA) and body weight in subjects with T2D, with a similar tolerability profile, regardless of whether they receive background MET or MET + SU.
- | Byetta (exenatide) / AstraZeneca, semaglutide SC once-daily (NN9536) / Novo Nordisk
Review, Journal: MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonist equal in the treatment of type 2 diabetes? (Pubmed Central) - Mar 18, 2020
Most GLP-1 receptor agonists (lixisenatide q.d., liraglutide q.d., exenatide q.w., dulaglutide q.w., albiglutide q.w., semaglutide q.w., all for s.c. injection, and the first oral preparation, oral semaglutide) have been examined in cardiovascular outcomes studies...Liraglutide, in addition, reduced cardiovascular and all-cause mortality. It is the purpose of the present review to describe clinically important differences, regarding pharmacokinetic behaviour, glucose-lowering potency, effectiveness of reducing body weight and controlling other cardiovascular risk factors, and of the influence of GLP-1 receptor agonist treatment on cardiovascular outcomes in patients either presenting with or without pre-existing cardiovascular disease (atherosclerotic, ischemic or congestive heart failure).
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Semaglutida semanal, Ozempic es el nombre comercial. Impresionantes resultados en A1c, peso, protección renal y cardiovascular más lo que viene. Saludos (Twitter) - Mar 13, 2020
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens (clinicaltrials.gov) - Mar 9, 2020
P1, N=68, Active, not recruiting, Sponsor: Novo Nordisk A/S
It is the purpose of the present review to describe clinically important differences, regarding pharmacokinetic behaviour, glucose-lowering potency, effectiveness of reducing body weight and controlling other cardiovascular risk factors, and of the influence of GLP-1 receptor agonist treatment on cardiovascular outcomes in patients either presenting with or without pre-existing cardiovascular disease (atherosclerotic, ischemic or congestive heart failure). Recruiting --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
[VIRTUAL] A POPULATION-ADJUSTED INDIRECT COMPARISON OF CARDIOVASCULAR BENEFITS BETWEEN ONCE-WEEKLY SEMAGLUTIDE AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1832;
The main analysis demonstrated a significantly lower risk of MACE for semaglutide vs placebo in a population with lower prevalence of pre-existing CV disease than that in the pre-specified primary analysis in the SUSTAIN 6 trial. Reduction in MACE with semaglutide was numerically, though not statistically significantly, greater than with dulaglutide.
- metformin / Generic mfg., Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
[VIRTUAL] COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VS. CANAGLIFLOZIN 300 MG IN PATIENTS WITH TYPE 2 DIABETES IN A CANADIAN SETTING () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1753;
OBJECTIVES: We estimated the cost-effectiveness of once-weekly semaglutide 1 mg vs. canagliflozin 300 mg in Canada from the payer and societal perspectives. Using two different models and modeling approaches (cohort and microsimulation), semaglutide 1 mg was found to be cost-effective compared to canagliflozin 300 mg for the treatment of patients with T2D uncontrolled on metformin in Canada.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Review, Journal: Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. (Pubmed Central) - Mar 2, 2020
In SUSTAIN 6, involving patients at high risk of cardiovascular disease, semaglutide significantly decreased the occurrence of cardiovascular events compared with placebo/standard of care (hazard ratio 0.74, p < 0.001 for noninferiority). Through a comprehensive phase 3 clinical trial program, we have a detailed understanding of semaglutide's efficacy, safety, cardiovascular effects and comparative role in the treatment of type 2 diabetes.
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN) (clinicaltrials.gov) - Mar 1, 2020
P=N/A, N=335, Completed, Sponsor: Novo Nordisk A/S
Through a comprehensive phase 3 clinical trial program, we have a detailed understanding of semaglutide's efficacy, safety, cardiovascular effects and comparative role in the treatment of type 2 diabetes. Active, not recruiting --> Completed
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY) (clinicaltrials.gov) - Feb 28, 2020
P=N/A, N=730, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese (clinicaltrials.gov) - Feb 27, 2020
P1, N=96, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Jun 2020 | Trial primary completion date: Jan 2020 --> Jun 2020
- |||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (clinicaltrials.gov) - Feb 27, 2020
P3, N=160, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Retrospective data, Journal: Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. (Pubmed Central) - Feb 25, 2020
P3
In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile. Trial registry Clinicaltrials.gov, Identifying number: NCT01720446, Date of registration: October 29, 2012.
- || Clinical, Journal, HEOR: Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden. (Pubmed Central) - Feb 24, 2020
In patients inadequately controlled on basal insulin, the analyses versus lixisenatide were based on results from an NMA, as no head-to-head clinical trial has been conducted for this comparison. These CEA results show that once-weekly semaglutide is a cost-effective GLP-1 RA therapy for the treatment of T2D in patients inadequately controlled on metformin or basal insulin, addressing many current clinician, patient, and payer unmet needs in Sweden.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Lanzamiento de semaglutida en colombia. Una herramienta mas para control metabolico y de peso de nuestros pacientes #ozempic @novonordiskfond @novonordisk (Twitter) - Feb 22, 2020
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, HEOR, Real-world evidence, Real-world: Real-world Health Outcomes in Canadian Patients Using Semaglutide (clinicaltrials.gov) - Feb 20, 2020
P=N/A, N=1133, Completed, Sponsor: LMC Diabetes & Endocrinology Ltd.
These CEA results show that once-weekly semaglutide is a cost-effective GLP-1 RA therapy for the treatment of T2D in patients inadequately controlled on metformin or basal insulin, addressing many current clinician, patient, and payer unmet needs in Sweden. Active, not recruiting --> Completed
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New trial, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY) (clinicaltrials.gov) - Feb 9, 2020
P, N=730, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P4 trial: The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity (clinicaltrials.gov) - Feb 9, 2020
P4, N=40, Recruiting, Sponsor: University Medical Centre Ljubljana
- | metformin / Generic mfg., Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Journal, HEOR: Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK. (Pubmed Central) - Feb 7, 2020
Active, not recruiting --> Completed Compared with treatment with dulaglutide, once-weekly semaglutide represents a cost-effective option for treating people with T2DM not achieving glycaemic control on metformin in the UK, projected to both improve clinical outcomes and reduce costs.
- glimepiride / Generic mfg., semaglutide SC once-daily (NN9536) / Novo Nordisk
Novel Use of GLP-1 Receptor Agonist Therapy in MODY-1 (HNF4A Mutation) (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_3021;
He was switched to semaglutide 0.25 mg once weekly and was titrated to a maximum dose of 1 mg weekly over 8 weeks...To our knowledge this is the first report demonstrating the benefits of GLP-1 RA therapy in patients with the HNF4A mutations (MODY-1). Based on this report, it appears that GLP-1 RA therapy could be an effective therapy in patients with MODY-1.
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens (clinicaltrials.gov) - Feb 6, 2020
P1, N=78, Recruiting, Sponsor: Novo Nordisk A/S
Based on this report, it appears that GLP-1 RA therapy could be an effective therapy in patients with MODY-1. Not yet recruiting --> Recruiting
- || Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Novo's next-gen GLP-1 Ozempic smashes blockbuster barrier amid ramp-up for Rybelsus rollout https://t.co/Gu8a8OXYui (Twitter) - Feb 5, 2020
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide (clinicaltrials.gov) - Feb 5, 2020
P1, N=28, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
The Effect Of SemaglutideOnce WeeklyOn MACE and Blood Pressure By Race And Ethnicity: SUSTAIN 6 Post Hoc Analysis () - Feb 2, 2020 - Abstract #QDEM42020QDEM_44;
Not yet recruiting --> Recruiting Overall there was no evidence of a differential effect of semaglutide on risk reduction in MACE and its components and on BP acrossrace and ethnicity subgroupsin thispost hoc analysis.
- Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter 2 Inhibitor: A Post Hoc Analysis of SUSTAIN 9 () - Feb 2, 2020 - Abstract #QDEM42020QDEM_42;
In this post hoc analysis, SUSTAIN 9 data were analysed by background SGLT2is (empagliflozin, canagliflozin, dapagliflozin or other [ipragliflozin, luseogliflozin and tofogliflozin; drugs available only in Japan])... InsubjectswithT2Dalready receivinganSGLT2i,semaglutide generallyresultedin superior HbA1c and body weightreductions vs. placebo,regardless of background SGLT2i Therapy.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: STEP 7: Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity (clinicaltrials.gov) - Jan 30, 2020
P3, N=375, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P1 trial: A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens (clinicaltrials.gov) - Jan 22, 2020
P1, N=78, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Journal, HEOR: Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. (Pubmed Central) - Jan 21, 2020
InsubjectswithT2Dalready receivinganSGLT2i,semaglutide generallyresultedin superior HbA1c and body weightreductions vs. placebo,regardless of background SGLT2i Therapy. No abstract available
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND) (clinicaltrials.gov) - Jan 18, 2020
P=N/A, N=216, Completed, Sponsor: Novo Nordisk A/S
No abstract available Active, not recruiting --> Completed
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: SUSTAIN FORTE: A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (clinicaltrials.gov) - Jan 18, 2020
P3, N=964, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
FDA event: FDA Approves CVD Benefit for Once-Weekly Semaglutide - a huge advance for DM manatement! https://t.co/jKQnKUWttE via @medscape (Twitter) - Jan 17, 2020
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P1 trial: A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide (clinicaltrials.gov) - Jan 13, 2020
P1, N=28, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal, HEOR: The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain. (Pubmed Central) - Jan 13, 2020
Both doses of semaglutide were associated with comparable or lower costs of control versus sitagliptin when considering endpoints incorporating hypoglycemia and weight loss alongside glycemic control, and lower costs of control versus dulaglutide 1.5 mg for all endpoints in Spain. Plain language summary available for this article.
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: SURE CANADA: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice (clinicaltrials.gov) - Jan 13, 2020
P=N/A, N=400, Completed, Sponsor: Novo Nordisk A/S
Plain language summary available for this article. Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, HEOR, Real-world evidence, Real-world: Real-world Health Outcomes in Canadian Patients Using Semaglutide (clinicaltrials.gov) - Jan 7, 2020
P=N/A, N=1000, Active, not recruiting, Sponsor: LMC Diabetes & Endocrinology Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
🆕🆓 #openaccess research, Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes ➡️https://t.co/RyOTA8NCca @UoDMedicine Rory McCrimmon @novonordisk #semaglutide #canagliflozin #type2diabetes #bodycomposition #fatmass (Twitter) - Jan 6, 2020
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P2 trial: Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) (clinicaltrials.gov) - Jan 2, 2020
P2, N=50, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
SIMILAR EFFICACY AND GASTROINTESTINAL TOLERABILITY VERSUS EXPOSURE FOR ORAL AND SUBCUTANEOUS SEMAGLUTIDE (E-Poster Area) - Dec 29, 2019 - Abstract #ATTD2020ATTD_605;
Methods Population pharmacokinetic data were compared from four 30-week trials (SUSTAIN 1–3, SUSTAIN-Japan) of once-weekly s.c. semaglutide (0.5, 1.0 mg; N=1552) and six 26-week trials (PIONEER 1–3, 5, 8, 9) of once-daily oral semaglutide (3, 7, 14 mg; N=3003)...Exposure–response relationships were consistent across the SUSTAIN and PIONEER datasets, and even more consistent when using propensity-matched data. Conclusions Exposure–response relationships for oral and s.c. semaglutide efficacy and tolerability were similar; the greater variability in semaglutide plasma concentrations following oral administration does not impact response.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
It stand for "oh oh oh #OZEMPIC" #cancelonetflix @novonordisk (Twitter) - Dec 26, 2019
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date: FOCUS: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (clinicaltrials.gov) - Dec 23, 2019
P3, N=1500, Recruiting, Sponsor: Novo Nordisk A/S
Conclusions Exposure–response relationships for oral and s.c. semaglutide efficacy and tolerability were similar; the greater variability in semaglutide plasma concentrations following oral administration does not impact response. Trial completion date: May 2025 --> Nov 2025
- | Rybelsus (semaglutide oral) / Novo Nordisk, metformin / Generic mfg., Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: Oral semaglutide (Rybelsus) for type 2 diabetes. (Pubmed Central) - Dec 22, 2019
Trial completion date: May 2025 --> Nov 2025 No abstract available
- | Review, Journal: Drugs for type 2 diabetes. (Pubmed Central) - Dec 22, 2019
No abstract available No abstract available
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide SC once-daily (NN9536) / Novo Nordisk
[VIRTUAL] EFFECTS OF SEMAGLUTIDE VERSUS COMPARATORS ON CARDIOVASCULAR EVENTS ACROSS A CONTINUUM OF BASELINE CARDIOVASCULAR RISK: COMBINED ANALYSIS OF THE SUSTAIN AND PIONEER TRIALS (eAbstract Virtual Hall) - Dec 22, 2019 - Abstract #ACC2020ACC_6919;
Background: In patients with type 2 diabetes (T2D) at high risk of CV events, there were fewer major adverse CV events (MACE) with semaglutide vs placebo (HRs [95% CIs]: 0.74 [0.58;0.95] for subcutaneous, 0.79 [0.57;1.11] for oral semaglutide)... Semaglutide reduced the risk of MACE vs comparators in patients with T2D across baseline CV risk, including low CV risk.